Funding for Medical Research
and Clinical Trials
and Clinical Trials
Funding Details for Cancer
Use the contact information shown for the organization to apply for the funding.
Please notify CenTrial of any offer is incorrect or has expired.
Please notify CenTrial of any offer is incorrect or has expired.
Lung Adenocarcinoma (LUAD)
LUNGevity Foundation
Type of Organization: Foundation
Contact Name: Upal Basu Roy
Email Address: ubasuroy@LUNGevity.org
Funds Available for Clinical Trials: ✗ Research: ✔
1) hold a doctoral degree and faculty appointment (or equivalent) with an academic institution, including research institutions that are not formally associated with a university
2) have completed a postdoctoral training fellowship.
An applicant may be at any level of research experience and must be an independent, selfdirected researcher for whom their institution must provide space and other resources customary for independent investigators. The application must convey the commitment of the institution to the applicant and the proposed research activities. An applicant with an existing Rising Tide Foundation Award or a LUNGevity award that would be concurrent with Rising Tide/LUNGevity Award is not precluded from applying. Team Award Requirement: This is a team award and at least two institutions are required to be involved right from the LOI stage. One institution may serve as the primary institution. We recommend identifying one US and one non-US institution to develop the team. Please reach out to us if you have any questions about the team requirement. Geographical Restriction: As noted above, international teams are highly recommended, and the Award Program does not have any geographical restrictions. For US applicants only: Applicants are not required to be U.S. citizens or to be employed by a U.S. institution. At the time of application, if an applicant is employed by a U.S. institution, they must be a United States citizen or a foreign national holding one of the following visa immigration statuses: permanent resident (Green Card), exchange visitor (J-1), temporary worker in a specialty occupation (H-1, H-1B), Canadian or Mexican citizen engaging in professional activities (TC or TN), or temporary worker with extraordinary abilities in the sciences (O-1). This applicant/awardee must be employed by a U.S. institution throughout the duration of the award term. The application must be submitted in English.
Other info: The Rising Tide/LUNGevity Team Award to Target Mechanisms of Resistance will fund high-impact interventional clinical trials that seek to develop therapeutic strategies targeting shared mechanisms of resistance in oncogene-driven lung adenocarcinoma (LUAD). Projects funded are expected to further our knowledge of shared mechanisms of resistance across oncogene-driven LUAD and how they can be targeted using novel pharmaceutical agents (monotherapies or combination therapies). The program has no geographical restrictions and is open to both US and non-US applicants.
Applications Open Early Next Year
LUNGevity Foundation
Type of Organization: Foundation
Contact Name: Upal Basu Roy
Email Address: ubasuroy@LUNGevity.org
Funds Available for Clinical Trials: ✗ Research: ✔
Funding Details
Requirements: Education and Experience: At the time of the grant term, the applicant, who must be a principal investigator for the proposed research, must:1) hold a doctoral degree and faculty appointment (or equivalent) with an academic institution, including research institutions that are not formally associated with a university
2) have completed a postdoctoral training fellowship.
An applicant may be at any level of research experience and must be an independent, selfdirected researcher for whom their institution must provide space and other resources customary for independent investigators. The application must convey the commitment of the institution to the applicant and the proposed research activities. An applicant with an existing Rising Tide Foundation Award or a LUNGevity award that would be concurrent with Rising Tide/LUNGevity Award is not precluded from applying. Team Award Requirement: This is a team award and at least two institutions are required to be involved right from the LOI stage. One institution may serve as the primary institution. We recommend identifying one US and one non-US institution to develop the team. Please reach out to us if you have any questions about the team requirement. Geographical Restriction: As noted above, international teams are highly recommended, and the Award Program does not have any geographical restrictions. For US applicants only: Applicants are not required to be U.S. citizens or to be employed by a U.S. institution. At the time of application, if an applicant is employed by a U.S. institution, they must be a United States citizen or a foreign national holding one of the following visa immigration statuses: permanent resident (Green Card), exchange visitor (J-1), temporary worker in a specialty occupation (H-1, H-1B), Canadian or Mexican citizen engaging in professional activities (TC or TN), or temporary worker with extraordinary abilities in the sciences (O-1). This applicant/awardee must be employed by a U.S. institution throughout the duration of the award term. The application must be submitted in English.
Other info: The Rising Tide/LUNGevity Team Award to Target Mechanisms of Resistance will fund high-impact interventional clinical trials that seek to develop therapeutic strategies targeting shared mechanisms of resistance in oncogene-driven lung adenocarcinoma (LUAD). Projects funded are expected to further our knowledge of shared mechanisms of resistance across oncogene-driven LUAD and how they can be targeted using novel pharmaceutical agents (monotherapies or combination therapies). The program has no geographical restrictions and is open to both US and non-US applicants.
Applications Open Early Next Year